MTD Mettler Toledo
World-class weighing franchise, but the price already assumes a decade of flawless growth and margins.
The story
Mettler-Toledo is the global leader in precision weighing and lab and industrial instruments. Its moat rests on a large installed base, a service and consumables business that brings in recurring revenue, and pricing power built on its Spinnaker sales and productivity programs. It is a mature, cash-generative franchise. Recent organic growth has been weak (about 1% 5-year CAGR, hurt by the post-COVID lab and China slump), but long-run mid-single-digit growth should resume as pharma and biotech capex, automation, and reshoring recover. Heavy buybacks fund shareholder returns rather than reinvestment.
A 12-year horizon fits a durable franchise with sticky service revenue. Growth starts at 6%, reflecting lab demand recovery plus pricing, and fades to 4% in the terminal year, below the risk-free rate. The margin edges up from 28% to 31% through pricing and productivity, not to a peak. Sales-to-capital of 2.5 reflects asset-light incremental growth on top of a roughly 45% ROIC. Even with generous drivers, value lands well below the price: the market is paying about 36x NOPAT, which assumes near-perfect execution.
Value drivers
| Revenue growth (Y1) | 6.0% |
| Terminal growth | 4.0% |
| Forecast horizon | 12y |
| Target operating margin | 31.0% |
| Years to target margin | 5 |
| Sales-to-capital | 2.50 |
| Beta | 0.95 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 9.2% |
| Terminal WACC | 9.4% |
Valuation bridge
| PV of explicit FCFF | 9.26B |
| PV of terminal value | 9.56B |
| Equity value | 16.74B |
| ÷ shares → per share | $835.28 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 4.38B | 6.0% | 28.8% | 1.04B | 99.21M | 945.77M | 866.48M |
| 2 | 4.64B | 5.8% | 29.3% | 1.13B | 101.98M | 1.03B | 860.46M |
| 3 | 4.90B | 5.6% | 29.9% | 1.21B | 104.54M | 1.11B | 852.54M |
| 4 | 5.17B | 5.5% | 30.4% | 1.30B | 106.87M | 1.20B | 842.79M |
| 5 | 5.44B | 5.3% | 31.0% | 1.40B | 108.94M | 1.29B | 831.30M |
| 6 | 5.71B | 5.1% | 31.0% | 1.47B | 110.73M | 1.36B | 802.60M |
| 7 | 6.00B | 4.9% | 31.0% | 1.54B | 112.21M | 1.43B | 773.55M |
| 8 | 6.28B | 4.7% | 31.0% | 1.61B | 113.36M | 1.50B | 744.26M |
| 9 | 6.56B | 4.5% | 31.0% | 1.69B | 114.15M | 1.57B | 714.84M |
| 10 | 6.85B | 4.4% | 31.0% | 1.76B | 114.57M | 1.65B | 685.39M |
| 11 | 7.14B | 4.2% | 31.0% | 1.83B | 114.59M | 1.72B | 656.01M |
| 12 | 7.42B | 4.0% | 31.0% | 1.91B | 114.19M | 1.79B | 626.80M |
Key risks
- Pharma and biotech capex and China lab demand stay depressed, keeping organic growth near 1-3%
- Tariffs, FX, and input costs squeeze margins that are already near the high end of the industry
- Multiple compression: a 36x NOPAT valuation leaves no room for a growth miss, and leverage from buybacks increases downside
Catalysts
- Lab and bioprocessing instrument replacement cycle plus GLP-1/reshoring capex driving a return to 6-8% organic growth
- Continued buybacks and Spinnaker/SternDrive margin gains lifting EPS above expectations